A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding

Yao Chun Hsu, Chin Lin Perng, Tzeng Huey Yang, Chaur Shine Wang, Wei Lun Hsu, Huei Tang Wu, Yang Chih Cheng, Ming Feng Chiang, Hwai-Jeng Lin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial. The aim was to compare the clinical effectiveness of two doses of infusional pantoprazole in peptic ulcer bleeding. Methods: Peptic ulcer patients (n = 120) with bleeding stigmata were enrolled after successful endoscopic therapy. After an initial bolus injection of 80 mg pantoprazole, patients were randomized to receive continuously infused pantoprazole at either 192 mg day-1 or 40 mg every 6 h (i.e. 160 mg day-1) for 3 days. Clinical outcomes between the two groups within 14 days were compared, with 14-day recurrent bleeding regarded as the primary end-point. Results: Both groups (n = 60 each) were well matched in demographic and clinical factors upon entry. Bleeding totally recurred in 11 (9.2%) patients, with six (10%) in the 192 mg day-1 group and five (8.3%) in the 160 mg day-1 group (relative risk of bleeding recurrence between two treatments 1.2; 95% CI 0.39, 3.72). All secondary outcomes between the two groups were similar, including the amount of blood transfusion (mean 1179 ml vs. 1203 ml, P > 0.1), hospital stay (mean 9.5 days vs. 9.9 days, P > 0.1), need for surgery (n = 1 vs. n = 0, P > 0.1), and mortality (n = 1 vs. n = 0, P > 0.1). Conclusions: Following endoscopic haemostasis, infusional pantoprazole at either 192 mg day-1 or 40 mg every 6 h appear similar.

Original languageEnglish
Pages (from-to)245-251
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Volume69
Issue number3
DOIs
Publication statusPublished - Mar 2010
Externally publishedYes

Fingerprint

Peptic Ulcer
Randomized Controlled Trials
Hemorrhage
Endoscopic Hemostasis
Christianity
Proton Pump Inhibitors
Blood Transfusion
pantoprazole
Length of Stay
Demography
Recurrence
Injections
Mortality
Therapeutics

Keywords

  • Pantoprazole
  • Peptic ulcer bleeding
  • Proton pump inhibitor
  • Recurrent bleeding

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. / Hsu, Yao Chun; Perng, Chin Lin; Yang, Tzeng Huey; Wang, Chaur Shine; Hsu, Wei Lun; Wu, Huei Tang; Cheng, Yang Chih; Chiang, Ming Feng; Lin, Hwai-Jeng.

In: British Journal of Clinical Pharmacology, Vol. 69, No. 3, 03.2010, p. 245-251.

Research output: Contribution to journalArticle

Hsu, Yao Chun ; Perng, Chin Lin ; Yang, Tzeng Huey ; Wang, Chaur Shine ; Hsu, Wei Lun ; Wu, Huei Tang ; Cheng, Yang Chih ; Chiang, Ming Feng ; Lin, Hwai-Jeng. / A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. In: British Journal of Clinical Pharmacology. 2010 ; Vol. 69, No. 3. pp. 245-251.
@article{821aba9c137d451ca1cf4883b1c91c6e,
title = "A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding",
abstract = "Aim: The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial. The aim was to compare the clinical effectiveness of two doses of infusional pantoprazole in peptic ulcer bleeding. Methods: Peptic ulcer patients (n = 120) with bleeding stigmata were enrolled after successful endoscopic therapy. After an initial bolus injection of 80 mg pantoprazole, patients were randomized to receive continuously infused pantoprazole at either 192 mg day-1 or 40 mg every 6 h (i.e. 160 mg day-1) for 3 days. Clinical outcomes between the two groups within 14 days were compared, with 14-day recurrent bleeding regarded as the primary end-point. Results: Both groups (n = 60 each) were well matched in demographic and clinical factors upon entry. Bleeding totally recurred in 11 (9.2{\%}) patients, with six (10{\%}) in the 192 mg day-1 group and five (8.3{\%}) in the 160 mg day-1 group (relative risk of bleeding recurrence between two treatments 1.2; 95{\%} CI 0.39, 3.72). All secondary outcomes between the two groups were similar, including the amount of blood transfusion (mean 1179 ml vs. 1203 ml, P > 0.1), hospital stay (mean 9.5 days vs. 9.9 days, P > 0.1), need for surgery (n = 1 vs. n = 0, P > 0.1), and mortality (n = 1 vs. n = 0, P > 0.1). Conclusions: Following endoscopic haemostasis, infusional pantoprazole at either 192 mg day-1 or 40 mg every 6 h appear similar.",
keywords = "Pantoprazole, Peptic ulcer bleeding, Proton pump inhibitor, Recurrent bleeding",
author = "Hsu, {Yao Chun} and Perng, {Chin Lin} and Yang, {Tzeng Huey} and Wang, {Chaur Shine} and Hsu, {Wei Lun} and Wu, {Huei Tang} and Cheng, {Yang Chih} and Chiang, {Ming Feng} and Hwai-Jeng Lin",
year = "2010",
month = "3",
doi = "10.1111/j.1365-2125.2009.03575.x",
language = "English",
volume = "69",
pages = "245--251",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding

AU - Hsu, Yao Chun

AU - Perng, Chin Lin

AU - Yang, Tzeng Huey

AU - Wang, Chaur Shine

AU - Hsu, Wei Lun

AU - Wu, Huei Tang

AU - Cheng, Yang Chih

AU - Chiang, Ming Feng

AU - Lin, Hwai-Jeng

PY - 2010/3

Y1 - 2010/3

N2 - Aim: The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial. The aim was to compare the clinical effectiveness of two doses of infusional pantoprazole in peptic ulcer bleeding. Methods: Peptic ulcer patients (n = 120) with bleeding stigmata were enrolled after successful endoscopic therapy. After an initial bolus injection of 80 mg pantoprazole, patients were randomized to receive continuously infused pantoprazole at either 192 mg day-1 or 40 mg every 6 h (i.e. 160 mg day-1) for 3 days. Clinical outcomes between the two groups within 14 days were compared, with 14-day recurrent bleeding regarded as the primary end-point. Results: Both groups (n = 60 each) were well matched in demographic and clinical factors upon entry. Bleeding totally recurred in 11 (9.2%) patients, with six (10%) in the 192 mg day-1 group and five (8.3%) in the 160 mg day-1 group (relative risk of bleeding recurrence between two treatments 1.2; 95% CI 0.39, 3.72). All secondary outcomes between the two groups were similar, including the amount of blood transfusion (mean 1179 ml vs. 1203 ml, P > 0.1), hospital stay (mean 9.5 days vs. 9.9 days, P > 0.1), need for surgery (n = 1 vs. n = 0, P > 0.1), and mortality (n = 1 vs. n = 0, P > 0.1). Conclusions: Following endoscopic haemostasis, infusional pantoprazole at either 192 mg day-1 or 40 mg every 6 h appear similar.

AB - Aim: The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial. The aim was to compare the clinical effectiveness of two doses of infusional pantoprazole in peptic ulcer bleeding. Methods: Peptic ulcer patients (n = 120) with bleeding stigmata were enrolled after successful endoscopic therapy. After an initial bolus injection of 80 mg pantoprazole, patients were randomized to receive continuously infused pantoprazole at either 192 mg day-1 or 40 mg every 6 h (i.e. 160 mg day-1) for 3 days. Clinical outcomes between the two groups within 14 days were compared, with 14-day recurrent bleeding regarded as the primary end-point. Results: Both groups (n = 60 each) were well matched in demographic and clinical factors upon entry. Bleeding totally recurred in 11 (9.2%) patients, with six (10%) in the 192 mg day-1 group and five (8.3%) in the 160 mg day-1 group (relative risk of bleeding recurrence between two treatments 1.2; 95% CI 0.39, 3.72). All secondary outcomes between the two groups were similar, including the amount of blood transfusion (mean 1179 ml vs. 1203 ml, P > 0.1), hospital stay (mean 9.5 days vs. 9.9 days, P > 0.1), need for surgery (n = 1 vs. n = 0, P > 0.1), and mortality (n = 1 vs. n = 0, P > 0.1). Conclusions: Following endoscopic haemostasis, infusional pantoprazole at either 192 mg day-1 or 40 mg every 6 h appear similar.

KW - Pantoprazole

KW - Peptic ulcer bleeding

KW - Proton pump inhibitor

KW - Recurrent bleeding

UR - http://www.scopus.com/inward/record.url?scp=76649092694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649092694&partnerID=8YFLogxK

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-76649092694&origin=resultslist&sort=plf-f&src=s&st1=A+randomized+controlled+trial+comparing+two+different+dosages+of+infusional+pantoprazole+in+peptic+ulcer+bleeding&st2=&sid=E7E90621DC65C68C8B43DC81C380F526.aXczxbyuHHiXgaIW6Ho7g%3a5010&sot=b&sdt=b&sl=120&s=TITLE%28A+randomized+controlled+trial+comparing+two+different+dosages+of+infusional+pantoprazole+in+peptic+ulcer+bleeding%29&relpos=0&citeCnt=6&searchTerm=#

U2 - 10.1111/j.1365-2125.2009.03575.x

DO - 10.1111/j.1365-2125.2009.03575.x

M3 - Article

VL - 69

SP - 245

EP - 251

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 3

ER -